ID   H82R
AC   CVCL_RS66
DR   cancercelllines; CVCL_RS66
DR   Wikidata; Q54872227
RX   PubMed=27610620;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>T); ClinVar=VCV000237948; Zygosity=Unspecified; Note=Impairs TP53 splicing dramatically (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1591 ! NCI-H82
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 11
//
RX   PubMed=27610620; DOI=10.1371/journal.pone.0162925;
RA   Yan F., Pang J.-X., Peng Y., Molina J.R., Yang P., Liu S.-J.;
RT   "Elevated cellular PD1/PD-L1 expression confers acquired resistance to
RT   cisplatin in small cell lung cancer cells.";
RL   PLoS ONE 11:E0162925-E0162925(2016).
//